首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells
【2h】

Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells

机译:中药JP-1在A549肺腺癌细胞中激活p53 / miR-34a抑癌轴。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so forth. Its expression is deficient in many types of cancers including LADC. Here, we show that a Chinese herbal formula JP-1 activates p53/miR-34a axis in A549 human LADC cells (p53 wild-type). Treatment with JP-1 induces p53 and its downstream p21 and BAX proteins as well as the miR-34a, resulting in growth inhibition, colony formation reduction, migration repression, and apoptosis induction. Accordingly, the decreases of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL were observed. Moreover, JP-1 activates AMPKα and reduces mTOR activity, implying its inhibitory effect on the energy-sensitive protein synthesis and cell proliferation signaling. Our results show that JP-1 activates p53/miR-34a tumor suppressor axis and decreases proteins related to proliferation, apoptosis resistance, and metastasis, suggesting its potential as a complementary medicine for LADC treatment.
机译:肺癌是全球癌症死亡的主要原因;最常见的病理类型是肺腺癌(LADC)。尽管近期在靶向治疗方面取得了进展,但由于不可避免的复发和耐药性,大多数LADC患者最终死亡。迫切需要具有循证分子机制的新型补充剂。 MiR-34a是重要的p53下游肿瘤抑制因子,可调节细胞凋亡,细胞周期,EMT(上皮间充质转化)等。它的表达在包括LADC在内的许多类型的癌症中均不足。在这里,我们显示了中药配方JP-1激活A549人LADC细胞(p53野生型)中的p53 / miR-34a轴。 JP-1处理可诱导p53及其下游p21和BAX蛋白以及miR-34a,从而抑制生长,抑制菌落形成,抑制迁移和诱导细胞凋亡。因此,观察到miR-34a下游靶标例如CDK6,SIRT1,c-Myc,存活蛋白,Snail和AXL的减少。此外,JP-1激活AMPKα并降低mTOR活性,暗示其对能量敏感蛋白合成和细胞增殖信号的抑制作用。我们的结果表明,JP-1激活p53 / miR-34a肿瘤抑制因子轴,并减少与增殖,凋亡抗性和转移相关的蛋白质,表明其作为LADC治疗的辅助药物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号